FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1776-1780 June 19, 1997 Number 25 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Randomized trials of colony-stimulating factors in febrile patients with neutropenia after chemotherapy have not consistently shown clinical benefit. Nevertheless, the use of colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is widespread.

Methods We performed a randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor (G-CSF) in afebrile outpatients with severe chemotherapy-induced neutropenia. We measured the number of days of neutropenia, rate of hospitalization, number of days in the hospital, number of days the patient received parenteral antibiotics, and number of culture-positive infections.

Results We randomly assigned 138 patients to receive G-CSF (n = 71) or placebo (n = 67). The median time to an absolute neutrophil count higher than 500 per cubic millimeter was significantly shorter for patients who received G-CSF (two days, vs. four days for the patients given placebo). However, there was no effect on the rate of hospitalization, number of days in the hospital, duration of treatment with parenteral antibiotics, or number of culture-positive infections.

Conclusions Routine therapeutic application of G-CSF in afebrile patients with severe neutropenia can reduce the duration of neutropenia, but this does not appear to provide practical clinical benefit.

Full Text of this Article

Related Letters:

Granulocyte Colony-Stimulating Factor in Afebrile Patients with Neutropenia
Cabanillas F., Hartmann L. C., Suman V. J., The North Central Cancer Treatment Group
Extract | Full Text  
N Engl J Med 1997; 337:1319-1320, Oct 30, 1997. Correspondence

This article has been cited by other articles:

• Kuderer, N. M., Dale, D. C., Crawford, J., Lyman, G. H. (2007). Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. JCO 25: 3158-3167 [Abstract] [Full Text]  
• Boleti, E., Mead, G. (2007). ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 18: 376-380 [Abstract] [Full Text]  
• Okazaki, T., Ebihara, S., Asada, M., Kanda, A., Sasaki, H., Yamaya, M. (2006). Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 18: 1-9 [Abstract] [Full Text]  
• Du, X. L., Lairson, D. R., Begley, C. E., Fang, S. (2005). Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort. JCO 23: 8620-8628 [Abstract] [Full Text]  
• Inagaki, K., Oda, T., Naka, Y., Shinkai, H., Komatsu, N., Iwamura, H. (2004). Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood 104: 58-64 [Abstract] [Full Text]  
• Kuramoto, K., Follmann, D. A., Hematti, P., Sellers, S., Agricola, B. A., Metzger, M. E., Donahue, R. E., von Kalle, C., Dunbar, C. E. (2004). Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood 103: 4070-4077 [Abstract] [Full Text]  
• Cormican, L.J., Schey, S., Milburn, H.J. (2004). G-CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia. Eur Respir J 23: 649-650 [Abstract] [Full Text]  
• Jones, B., Adams, S., Miller, G. T., Jesson, M. I., Watanabe, T., Wallner, B. P. (2003). Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 102: 1641-1648 [Abstract] [Full Text]  
• Stanford, B. L, Zondor, S. D, Cobos, E. (2003). Is pegfilgrastim appropriate for the treatment of established febrile neutropenia?. J Oncol Pharm Pract 9: 113-119 [Abstract]  
• Relling, M. V., Boyett, J. M., Blanco, J. G., Raimondi, S., Behm, F. G., Sandlund, J. T., Rivera, G. K., Kun, L. E., Evans, W. E., Pui, C.-H. (2003). Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101: 3862-3867 [Abstract] [Full Text]  
• Smith, T. J., Hillner, B. E. (2001). Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways. JCO 19: 2886-2897 [Abstract] [Full Text]  
• Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro, (2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO 18: 3558-3585 [Full Text]  
• Levy, O. (2000). Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood 96: 2664-2672 [Abstract] [Full Text]  
• Bennett, C. L., Weeks, J. A., Somerfield, M. R., Feinglass, J., Smith, T. J. (1999). Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines. JCO 17: 3676-3681 [Abstract] [Full Text]  
• Schroder, C. P., de Vries, E. G. E., Mulder, N. H., Willemse, P. H. B., Sleijfer, D. T., Hospers, G. A. P., van der Graaf, W. T. A. (1999). Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 43: 741-743 [Abstract] [Full Text]  
• Saven, A., Burian, C., Adusumalli, J., Koziol, J. A. (1999). Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia. Blood 93: 2471-2477 [Abstract] [Full Text]  
• Talcott, J. A. (1997). Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?. The Oncologist 2: 365-373 [Abstract] [Full Text]  
• Cabanillas, F., Hartmann, L. C., Suman, V. J., The North Central Cancer Treatment Group, (1997). Granulocyte Colony-Stimulating Factor in Afebrile Patients with Neutropenia. NEJM 337: 1319-1320 [Full Text]  
• O'Kane, D. J., Ebert, T. A., Hallaway, B. J., Roberts, S. G., Bhuiyan, A. K. M. J., Tenner, K. S. (1997). A laboratorian's perspective on evaluation and implementation of new laboratory tests. Clin. Chem. 43: 1771-1780 [Abstract] [Full Text]  
• (1997). G-CSF OF MINIMAL BENEFIT FOR CHEMOTHERAPY-INDUCED NEUTROPENIA. JWatch General 1997: 3-3 [Full Text]  
• Hoelzer, D. (1997). Hematopoietic Growth Factors -- Not Whether, but When and Where. NEJM 336: 1822-1824 [Full Text]